This segment focuses on the research, development, and commercialization of therapies for neurological and psychiatric disorders. Key products include HETLIOZ (tasimelteon) for non-24-hour sleep-wake disorders and Fanapt (iloperidone) for schizophrenia. Research and development activities include clinical trials for new indications such as jet lag disorder, autism spectrum disorder, and bipolar disorder. The segment utilizes advanced drug discovery techniques and clinical trial methodologies to develop and test novel therapeutics. Patient impact is significant, addressing unmet needs in sleep disorders and schizophrenia, improving patients' quality of life. Market positioning is strengthened by a focus on innovative therapies and a commitment to addressing challenging conditions. Future opportunities include expanding the indications for existing products and developing new treatments for neurological and psychiatric conditions. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials. Partnerships and collaborations may be pursued to enhance research and development efforts and expand market reach.

This segment encompasses the research and development of novel therapeutics across various therapeutic areas, including dermatology, gastroenterology, and oncology. The pipeline includes Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. VTR-297, a small molecule histone deacetylase inhibitor, is being developed for hematologic malignancies and other oncology indications. The segment utilizes advanced drug discovery platforms, including small molecule development and clinical trial methodologies. The patient impact is focused on addressing unmet medical needs in diverse disease areas, offering potential new treatment options. Market positioning is enhanced through a diversified pipeline and a focus on innovative therapies. Future opportunities include expanding the pipeline through internal research and external collaborations. Regulatory and clinical aspects involve conducting clinical trials and seeking regulatory approvals. Partnerships and collaborations are essential for advancing the pipeline and expanding market reach.